Rhodes N - Search Results

1

Monoclonal antibodies generated against recombinant ATM support kinase activity.

Alligood KJ, Milla M, Rhodes N, Ellis B, Kilpatrick KE, Lee A, Gilmer TM, Lansing TJ. Alligood KJ, et al. Among authors: rhodes n. Hybridoma. 2000 Aug;19(4):317-21. doi: 10.1089/027245700429864. Hybridoma. 2000. PMID: 11001404

2

Expression and purification of active recombinant ATM protein from transiently transfected mammalian cells.

Rhodes N, Gilmer TM, Lansing TJ. Rhodes N, et al. Protein Expr Purif. 2001 Aug;22(3):462-6. doi: 10.1006/prep.2001.1459. Protein Expr Purif. 2001. PMID: 11483009

3

A simple method for predicting serum protein binding of compounds from IC(50) shift analysis for in vitro assays.

Rusnak DW, Lai Z, Lansing TJ, Rhodes N, Gilmer TM, Copeland RA. Rusnak DW, et al. Among authors: rhodes n. Bioorg Med Chem Lett. 2004 May 3;14(9):2309-12. doi: 10.1016/j.bmcl.2004.01.103. Bioorg Med Chem Lett. 2004. PMID: 15081030

4

Defective potassium currents in ataxia telangiectasia fibroblasts.

Rhodes N, D'Souza T, Foster CD, Ziv Y, Kirsch DG, Shiloh Y, Kastan MB, Reinhart PH, Gilmer TM. Rhodes N, et al. Genes Dev. 1998 Dec 1;12(23):3686-92. doi: 10.1101/gad.12.23.3686. Genes Dev. 1998. PMID: 9851975 Free PMC article.

5

The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo.

Rusnak DW, Lackey K, Affleck K, Wood ER, Alligood KJ, Rhodes N, Keith BR, Murray DM, Knight WB, Mullin RJ, Gilmer TM. Rusnak DW, et al. Among authors: rhodes n. Mol Cancer Ther. 2001 Dec;1(2):85-94. Mol Cancer Ther. 2001. PMID: 12467226

6

Characterization of an Akt kinase inhibitor with potent pharmacodynamic and antitumor activity.

Rhodes N, Heerding DA, Duckett DR, Eberwein DJ, Knick VB, Lansing TJ, McConnell RT, Gilmer TM, Zhang SY, Robell K, Kahana JA, Geske RS, Kleymenova EV, Choudhry AE, Lai Z, Leber JD, Minthorn EA, Strum SL, Wood ER, Huang PS, Copeland RA, Kumar R. Rhodes N, et al. Cancer Res. 2008 Apr 1;68(7):2366-74. doi: 10.1158/0008-5472.CAN-07-5783. Cancer Res. 2008. PMID: 18381444

7

Identification of 4-(2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-{[(3S)-3-piperidinylmethyl]oxy}-1H-imidazo[4,5-c]pyridin-4-yl)-2-methyl-3-butyn-2-ol (GSK690693), a novel inhibitor of AKT kinase.

Heerding DA, Rhodes N, Leber JD, Clark TJ, Keenan RM, Lafrance LV, Li M, Safonov IG, Takata DT, Venslavsky JW, Yamashita DS, Choudhry AE, Copeland RA, Lai Z, Schaber MD, Tummino PJ, Strum SL, Wood ER, Duckett DR, Eberwein D, Knick VB, Lansing TJ, McConnell RT, Zhang S, Minthorn EA, Concha NO, Warren GL, Kumar R. Heerding DA, et al. Among authors: rhodes n. J Med Chem. 2008 Sep 25;51(18):5663-79. doi: 10.1021/jm8004527. J Med Chem. 2008. PMID: 18800763

8

Defective G2 checkpoint function in cells from individuals with familial cancer syndromes.

Paules RS, Levedakou EN, Wilson SJ, Innes CL, Rhodes N, Tlsty TD, Galloway DA, Donehower LA, Tainsky MA, Kaufmann WK. Paules RS, et al. Among authors: rhodes n. Cancer Res. 1995 Apr 15;55(8):1763-73. Cancer Res. 1995. PMID: 7712486

9

Serum starved v-mos-transformed cells are unable to appropriately downregulate cyclins and CDKs.

Rhodes N, Innes CL, Propst F, Paules RS. Rhodes N, et al. Oncogene. 1997 Jun 26;14(25):3017-27. doi: 10.1038/sj.onc.1201158. Oncogene. 1997. PMID: 9223665

10

v-mos-transformed cells fail to enter quiescence but growth arrest in G1 following serum withdrawal.

Rhodes N, Hicks R, Kasenally AB, Innes CL, Paules RS, Propst F. Rhodes N, et al. Exp Cell Res. 1994 Jul;213(1):210-7. doi: 10.1006/excr.1994.1192. Exp Cell Res. 1994. PMID: 8020593

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

291 results

Search Page

Filters